17:12:00 EDT Thu 28 Mar 2024
Enter Symbol
or Name
USA
CA



Cybin Inc
Symbol CYBN
Shares Issued 186,152,974
Close 2023-01-31 C$ 0.50
Market Cap C$ 93,076,487
Recent Sedar Documents

Cybin receives OK for first-in-human dosing of CYB004

2023-02-01 09:53 ET - News Release

Mr. Doug Drysdale reports

CYBIN ANNOUNCES APPROVAL OF FIRST-IN-HUMAN DOSING OF ITS PROPRIETARY DMT MOLECULE CYB004

Cybin Inc. has received approval from an independent ethics committee in the Netherlands to initiate first-in-human dosing of its proprietary deuterated N,N-dimethyltryptamine (DMT) molecule, CYB004, through a protocol amendment to its continuing CYB004-E phase 1 trial. This clinical advancement marks the first time a deuterated DMT molecule will be evaluated in humans and further reduces Cybin's time to clinic with CYB004.

The phase 1 CYB004-E trial is being conducted at the Centre for Human Drug Research in the Netherlands and is the largest ever phase 1 DMT trial conducted to date.

In its regular form, DMT is an unstable molecule rapidly metabolized in the body, which significantly reduces its bioavailability. CYB004 has the potential to overcome the limitations of DMT. Based on preclinical studies, CYB004 has demonstrated an improved bioavailability and pharmacokinetic profile in comparison with DMT when administered through intravenous (IV) and inhaled routes. These studies also demonstrated that IV CYB004 has a longer duration of effect compared with DMT, indicating the potential to extend the therapeutic window and provide better dose optimization. By maximizing CYB004 as a deuterated molecule and improving upon the bioavailability of DMT, CYB004 has the potential to offer more convenient dosing methods through inhaled, subcutaneous or intramuscular routes of administration.

"This is a major milestone for our CYB004 program and for better understanding the potential therapeutic benefits of our proprietary deuterated DMT molecule for the treatment of generalized anxiety disorder," said Doug Drysdale, Cybin's chief executive officer. "The ability to evaluate our novel CYB004 molecule in humans at this early stage is a significant achievement in clinical development and will provide important insight into the pharmacokinetic and pharmacodynamic properties of CYB004, in addition to what we have already learned through our study of DMT. We expect to apply these findings to optimize dosing and delivery of CYB004 in future clinical trials, which supports our mission to bring this new investigational therapy to patients as quickly as possible."

Cybin secured a United States composition of matter patent covering CYB004 in February, 2022, that provides patent protection through 2041. The patent covers a range of deuterated forms of DMT and protects CYB004 as a putative new chemical entity.

"With strong intellectual property in place and promising preclinical data, we believe we have a solid clinical development path forward for CYB004. We will continue to focus our research on identifying the most convenient routes of administration while also maintaining an optimal therapeutic profile for this important molecule," concluded Mr. Drysdale.

The company plans to evaluate CYB004 for the treatment of generalized anxiety disorder with or without major depressive disorder.

Cybin will provide additional information on its CYB004 program, including an update on the phase 1 CYB004-E trial, at its upcoming virtual R&D (research and development) day on Feb. 28, 2023.

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The company is focused on progressing psychedelics to therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.